Instrument Inactif

Communiqués Capricor Therapeutics Inc Nasdaq

Actions

US14070B1017

Recherche biotechnologique et médicale

Communiqués

26/06	Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy	AQ
26/06	Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference	AQ
08/06	Capricor Therapeutics to Present at Upcoming Investor Conferences	AQ
29/05	Capricor Therapeutics : Expands Commercial Leadership Team	PU
12/05	Capricor: Q1 Earnings Snapshot	AQ
12/05	Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update	AQ
08/05	Capricor Therapeutics : Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy	PU
04/05	Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12	AQ
22/04	Capricor Therapeutics : American Academy of Neurology (AAN) 2026 Presentation	PU
22/04	Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting	AQ
13/03	Capricor Therapeutics : 2026 MDA Conference Presentation	PU
12/03	Capricor: Q4 Earnings Snapshot	AQ
12/03	Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update	AQ
12/03	Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy	AQ
10/03	Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA	AQ
09/03	Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12	AQ
24/02	Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference	AQ
05/02	Capricor Therapeutics : Investor Presentation - February 2026	PU
20/01	Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data	AQ
16/12	Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy	AQ
05/12	Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock	AQ
04/12	Capricor Therapeutics Announces Proposed Public Offering of Common Stock	AQ
03/12	Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy	AQ
24/11	Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025	AQ
10/11	Capricor: Q3 Earnings Snapshot	AQ